



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known					
				Application Number		10/600,957			
				Filing Date		June 20, 2003			
				First Named Inventor		POWIS, Garth			
				Group Art Unit		1642			
Examiner Name		Not yet assigned							
Sheet		1		of 2		Attorney Docket Number		126387.530	
U.S. PATENT DOCUMENTS									
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number	Kind Code (if known)						
BF		20030223980		Powis	12-04-2003				
BF		20020055131		Powis	05-09-2002				
FOREIGN PATENT DOCUMENTS									
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T	
		Office	Number						Kind Code (if known)
BF		PCT	US97-22292		POWIS				
BF		WO	91 04320		Aktibolaget, Astra	4/4/1991			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.							T
BF		Baker, A., et al.: "Thioredoxin, a gene found overexpressed in human cancer" Cancer Research 57(22):5162-5167 (1997)							
		Powis, G., et al.: "Selenium and the Thioredoxin Redox System" Oncology Research 9(6-7):303-312 (1997)							
		Gallegos, A., et al.: "Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells" Cancer Research 56(24):5765-5770 (1996)							
		Berggren, M., et al.: "Thioredoxin and Thioredoxin Reductase Gene Expression in Human Tumors and Cell Lines" Anticancer Research 16:3459-66, XP002062159 (Nov.-Dec. 1996)							
		Gasdaska, J.R., et al.: Cell Growth Differentiation (December 1995)							
		Tockman, et al.: Cancer Research (Suppl) 52: 2715-2718 (1992)							
		Oblong, J.E.: Cancer Chemoth Pharmacol, 34:434-438 (1994)							
		Gura: Science 278:1041-1042 (1997)							
		Jain: Sci. Am, 271:58-65 (1994)							
		Gasdaska, J.R.: Biochem Pharmacol; 52:1741-1747 (1996)							
		Hartwell, et al: Science: 278:1064-1068 (1997)							
		Kirkpatrick, D.L., "Mechanisms of Inhibition of the Thioredoxin Growth Factor System by Antitumor 2-Imidazolyl Disulfides" Biochemical Pharmacology: 55: 987-996 (1998)							
		Kirkpatrick, D. L., et al., "Stimulation of Apoptosis by a Redox Active Disulfide" Proc. Am. Association, Cancer Res. 36 (1995): 2541							
		Drexler, et al. Leukemia and Lymphoma, 9:1-25 (1993)							
		Embleton, et al.: Immunol. Ser. 23:181-207 (1984)							
		Curti, et al.: Crit. Rev. in Oncology/Hematology, 14:29-39 (1993)							
		Mustafa O., et al.: International Journal of Oncology, 8(5):883-888 (1996)							
		Freshney: Culture of Animal Cells, a Manual of Basic Technique, Alan R. Liss, Inc., Pg. 4 (1983)							
		Powis, G., et al.: Thioredoxin Redox Signalling: a Novel Target for Anti-Cancer Drug Development, Anti-Cancer Drugs, 7:121-126 (1996)							
BF		Mau, B.L., et al.: Biochem. Pharmacol., 43: 1613-1620 (1992)							

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known		
		Application Number	10/600,957	
		Filing Date	June 20, 2003	
		First Named Inventor	POWIS, Garth	
		Group Art Unit	1642	
		Examiner Name	Not yet assigned	
		Attorney Docket Number		126387.530
BF	Schallreuter, K.U. , Biochem Biophys Acta, 1504: 14-20 (1990)			
BF	Powis, et al., Oncology Research, 6 (10-11):539-44			
BF	Gadaska, P.Y., et al.: Biochem Biophys ACTA 1218:292-296 (1994)			
Examiner Signature	/Brandon Fetterolf/		Date Considered	09/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.